[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456267":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":31,"collaborators":7,"id":34,"slug":7,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":46,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Anne-Marie Dingemans, MD, PhD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+31107040704","a.dingemans@erasmusmc.nl",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":7,"country":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Erasmus MC","RECRUITING","Rotterdam","Netherlands",{"type":24,"coordinates":25},"Point",[26,27],4.47917,51.9225,{"lat":27,"lon":26},[30],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"type":11,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Anne-Marie Dingemans","MD, PhD","100456267",false,"NCT05221372","ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)","proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors","START-TKI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to understand the written informed and able to give informed consent\n* Locally advanced or metastatic NSCLC with oncogenic driver mutation\n* Treatment with TKI according to standard of care\n\nExclusion Criteria:\n\n* Unable to draw blood for study purposes","ALL","18 Years",{"count":44,"type":45},1300,"ESTIMATED","10 Years","OBSERVATIONAL","The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.",[50,51,52],"Non Small Cell Lung Cancer","Liquid Biopsy","Tyrosine Kinase Inhibitor","2022-02-02",{"date":55,"type":56},"2022-02-18","ACTUAL",{"date":58,"type":56},"2017-02-02",{"date":60,"type":45},"2031-01-01",{"name":5,"class":6},1]